ICH E6(R3): The new rules of sponsor oversight and quality management

The finalization of ICH E6(R3) marks a significant evolution in how regulators expect sponsors to demonstrate control, oversight, and quality in clinical trials. While many discussions about E6(R3) focus on innovation, decentralization, and risk-based approaches, two sponsor-focused sections are particularly important for Trial Master File (TMF) management:

• Section 3.9: Sponsor Oversight
• Section 3.10: Quality Management

In a nutshell, regulators now expect sponsors to maintain effective, risk‑based oversight of trial conduct including activities delegated to CROs, vendors, and sites.

These sections redefine the role of the sponsor from a passive recipient of documentation to an active steward of trial quality. They also elevate the TMF from a filing requirement to a primary source of evidence that oversight and quality management were designed, implemented, and maintained throughout the trial lifecycle.

This article explores what Sections 3.9 and 3.10 actually require of sponsors, how they work together, and why TMF management sits at the center of demonstrating compliance under E6(R3).

From checklist compliance to demonstrable oversight

Previous versions of ICH E6 were often interpreted through a checklist lens: ensure required documents exist, confirm they are filed, and demonstrate that procedures were followed. While this approach supported baseline compliance, it struggled to keep pace with increasingly complex trials, distributed data sources, and outsourced operating models.

E6(R3) deliberately shifts away from prescriptive documentation lists and toward principle-based expectations. This means that sponsors are expected to think critically about how trials are designed and managed, identify what truly matters for participant safety and data reliability, and implement controls that are proportionate to risk.

In this context, the TMF is no longer just an archive. It is the tangible record of how sponsor oversight and quality management were exercised in practice.

Section 3.9: Sponsor oversight

What sponsor oversight means under E6(R3)

Section 3.9 establishes a clear expectation: sponsors are responsible for ensuring that trial design, trial conduct, processes, and generated data are of sufficient quality to protect participants and support reliable results.

Importantly, this responsibility applies regardless of how activities are delegated. Sponsors may transfer tasks to CROs or service providers, but:

Accountability for oversight under R3 belongs to the sponsor, always.

Sponsor oversight under E6(R3) is not defined as constant intervention or exhaustive monitoring. Instead, it is expected to be fit for purpose, risk-based, and tailored to the complexity of the trial.

Key elements of sponsor oversight include:

Assessing the impact of trial decisions on participant safety and data reliability

• Defining which protocol deviations are considered important
• Ensuring appropriate escalation and follow-up of issues
• Selecting and overseeing investigators and service providers
• Applying quality assurance and quality control activities proportionate to risk

And this is important to remember: oversight is not a single, one and done activity. It is a continuous process that spans planning, conduct, and reporting. It is not one and done, it is ongoing.

Why sponsor oversight is inseparable from the TMF

While Section 3.9 does not explicitly prescribe how oversight should be documented, it makes clear that oversight must be demonstrable. In practice, the TMF is where that demonstration occurs.

Sponsor oversight becomes visible through records such as:

• Documentation of risk-based monitoring strategies
• Records of issue identification, escalation, and resolution
• Evidence of investigator and vendor selection and oversight
• Records of decisions that affected trial conduct or data handling
• Documentation of committee oversight, where applicable

A TMF that only contains static documents, with little evidence of decision-making or follow-up, may suggest that oversight was minimal or retrospective. Under E6(R3), that perception creates inspection risk.

Defining and managing important protocol deviations

A notable expectation in Section 3.9 is that sponsors must define trial-specific criteria for identifying “important” protocol deviations. These are deviations that could meaningfully impact participant rights, safety, or data reliability.

This requirement reinforces the idea that not all deviations are equal and that oversight should focus on what matters most. From a TMF perspective, this means:

• Important deviations should be identifiable
• Their assessment and impact should be documented
• Corrective actions and follow-up should be traceable

The absence of this documentation in the TMF may raise questions about whether deviation management was proactive or simply administrative.

Section 3.10: Quality management

Quality management as a system, not a function

Section 3.10 introduces a structured expectation for quality management that extends beyond traditional quality assurance or monitoring functions. Sponsors are required to implement a system to manage quality throughout all stages of the trial process.

Quality management under E6(R3) is rooted in quality by design and requires sponsors to:

• Identify factors that are critical to quality
• Proactively manage risks to those factors
• Apply controls that are proportionate to risk
• Review and adjust controls as the trial evolves
• Summarize and report significant quality issues and actions

This is not an abstract framework. It is intended to be operational, trial-specific, and visible in how trials are conducted.

Risk management as the foundation of quality management

Risk management is the core operational component of Section 3.10. Sponsors are expected to identify risks that could meaningfully impact critical-to-quality factors before the trial begins and to reassess those risks throughout trial conduct.

Risk management includes:

• Risk identification across processes, systems, and vendors
• Evaluation of likelihood, detectability, and impact
• Risk control through design, monitoring, training, and procedures
• Communication of risks and mitigation strategies
• Periodic review to confirm continued effectiveness
• Reporting of important quality issues and remedial actions

Each of these steps has implications for how the TMF is structured and maintained.

The TMF as evidence of quality management

Under E6(R3), quality management is not considered complete unless it is supported by records. The TMF is the primary repository for that evidence.

Examples of TMF content that support quality management include:

• Risk assessments and updates
• Monitoring plans and revisions
• Documentation of quality tolerance limits and thresholds
• Records of issue trending and systemic analysis
• Evidence of management review and decision-making
• Documentation of corrective and preventive actions

If these records are missing, incomplete, or created late, it becomes difficult to demonstrate that quality management was proactive rather than reactive.

How Sections 3.9 and 3.10 work together

Sponsor oversight and quality management are distinct but tightly connected. Section 3.9 focuses on the sponsor’s responsibility to oversee trial conduct and decision-making. Section 3.10 defines the system that enables that oversight to be effective, consistent, and risk-based.

In practical terms:

• Quality management provides the framework
• Sponsor oversight applies that framework to real-world decisions
• The TMF provides the evidence that both occurred

A sponsor may have robust procedures and training in place, but if the TMF does not reflect how those procedures were applied in the context of a specific trial, inspectors may question whether they were applied at all.

Implications for TMF under E6(R3): Completeness reinterpreted

One of the most important shifts introduced by E6(R3) is how TMF completeness should be interpreted. Completeness is no longer defined solely by the presence of a predefined list of documents.

Instead, completeness is assessed based on whether the TMF:

• Allows reconstruction of trial conduct
• Demonstrates sponsor oversight in action
• Shows how quality risks were identified and managed
• Supports the reliability of trial results

This means that two trials using the same reference model may legitimately have different TMF content, depending on their design, risk profile, and operating model.

E6(R3) places strong emphasis on timely collection and filing of essential records. Contemporaneous documentation supports credible oversight and reduces the risk of retrospective reconstruction.

From an inspection perspective, audit trails and metadata make it easier than ever to identify records that were created or modified long after the fact. A TMF that relies heavily on late-stage remediation may undermine confidence in both sponsor oversight and quality management.

E6(R3) explicitly acknowledges that sponsors often rely on CROs and other service providers. However, delegation does not transfer responsibility.

Sponsors are expected to:

• Assess the suitability of service providers
• Maintain access to relevant records and performance information
• Apply appropriate oversight to delegated activities
• Ensure that quality management principles are applied consistently

The TMF plays a critical role in demonstrating this oversight. Records that show active engagement, issue follow-up, and performance review are essential to supporting the sponsor’s accountability.

Implementation expectations: Applying E6(R3) in practice

ICH E6(R3) does not prescribe a single implementation date or mandate retroactive changes to all ongoing trials. Instead, regulators have positioned E6(R3) as a principle-based guideline that should be applied progressively and proportionately.

Sponsors are generally expected to:

• Design new trials in alignment with E6(R3) principles
• Demonstrate awareness of E6(R3) in ongoing trials
• Avoid practices that directly contradict R3 expectations
• Be able to explain their transition approach during inspection

For TMF teams, this means the focus should be on aligning documentation practices with how oversight and quality are actually performed, rather than attempting to mechanically “convert” legacy TMFs.

Even during the transition period, inspectors are increasingly attentive to whether E6(R3) principles are evident in trial records.

Areas of focus include:

• Whether sponsor oversight is visible and ongoing
• Whether quality management is proactive and risk-based
• Whether decisions and issues are documented clearly
• Whether the TMF supports timely access and trial reconstruction

Inspectors are not necessarily expecting perfect alignment with every aspect of E6(R3, but they are expecting coherence between stated processes and documented evidence.

That evolution in regulatory expectations is exactly why the product team at Montrium is placing such strong emphasis on risk management and sponsor oversight within eTMF Connect.

As ICH E6(R3) moves the industry away from retrospective proof and toward demonstrable, realtime oversight, the TMF must evolve from a place where compliance is recorded to a place where trial quality is actively shaped. eTMF Connect is being built with that future in mind; one where oversight, risk, and documentation are no longer treated as separate concerns, but as part of a single, connected ecosystem.

“We see E6(R3) as a turning point for how sponsors think about the TMF,” the Montrium product team explains.

“The expectation is no longer just that you can show what happened at the end of a trial, but that you can see, at any point, how risk is being managed and how quality decisions are influencing execution. Our focus is on making the TMF a living reflection of those decisions, not a retrospective record of them.” - Charles Fortier, Director of Product at Montrium

In that sense, eTMF Connect is not just evolving to meet new guidance, but to support a broader shift in how trial oversight and quality management are practiced under E6(R3).

Conclusion: The TMF as proof of oversight and quality

ICH E6(R3) does not introduce new documentation requirements for the sake of documentation, it raises expectations for how sponsors think about, implement, and demonstrate oversight and quality.

Sections 3.9 and 3.10 make it clear that sponsor oversight and quality management are continuous responsibilities that must be visible in trial records. The TMF is where those responsibilities are ultimately assessed.

For sponsors and TMF professionals, this represents a meaningful shift. A TMF that simply proves documents exist is no longer sufficient. A TMF must tell the story of how a trial was designed, overseen, and controlled in a way that protected participants and ensured reliable results.

Under E6(R3), the TMF is no longer just a compliance artifact. It is the narrative of trial quality itself.

This is the beginning of a beautiful evolution in TMF management.

Frequently asked questions

What does ICH E6(R3) require for sponsor oversight?

ICH E6(R3) Section 3.9 requires sponsors to maintain continuous, risk-based oversight of all trial activities, including those delegated to CROs and service providers. Sponsors must assess the impact of trial decisions on participant safety and data reliability, define criteria for important protocol deviations, and ensure appropriate escalation and follow-up of issues. Accountability for oversight cannot be transferred, even when tasks are fully outsourced.

What is the difference between Section 3.9 and Section 3.10 in ICH E6(R3)?

Section 3.9 addresses sponsor oversight: the sponsor's responsibility to monitor and control trial conduct and decision-making. Section 3.10 addresses quality management: the system sponsors must implement to identify critical-to-quality factors, proactively manage risks, and apply controls proportionate to those risks. In practice, quality management (3.10) provides the

framework, and sponsor oversight (3.9) applies that framework to real-world trial decisions. Both must be documented in the TMF.

How does ICH E6(R3) change what TMF completeness means?

Under previous interpretations of ICH E6, TMF completeness was largely defined by the presence of a predefined document list. ICH E6(R3) redefines completeness based on whether the TMF allows reconstruction of trial conduct, demonstrates that sponsor oversight was active and ongoing, shows how quality risks were identified and managed, and supports the reliability of trial results. Two trials using the same reference model may legitimately have different TMF content depending on their design and risk profile.

Does ICH E6(R3) apply to ongoing trials or only new ones?

ICH E6(R3) does not mandate retroactive changes to all ongoing trials or prescribe a single implementation date. Sponsors are generally expected to design new trials in alignment with E6(R3) principles, demonstrate awareness of those principles in ongoing trials, and be able to explain their transition approach during inspection. Inspectors are increasingly attentive to whether E6(R3) principles, particularly proactive oversight and risk-based quality management, are evident in trial records, even during the transition period.

What TMF records demonstrate sponsor oversight and quality management under ICH E6(R3)?

Records that support sponsor oversight under Section 3.9 include documentation of risk-based monitoring strategies, records of issue identification and resolution, evidence of investigator and vendor selection and performance review, and documentation of decisions that affected trial conduct or data handling. Records that support quality management under Section 3.10 include risk assessments and updates, monitoring plans and revisions, quality tolerance limit documentation, issue trending records, and corrective and preventive action documentation. Records that are missing, incomplete, or created retrospectively may indicate that oversight was reactive rather than continuous.